Evaluation status available after sign-in
About the journal
BMC Cancer is an open-access journal published by BMC in United Kingdom, publishing in english. It is listed in DOAJ and MEDLINE and PUBMED according to the sources read. Declared publication charge: 3,150 EUR. Declared review time at DOAJ: 19 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- BMC
- ISSN
- 1471-2407
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,150 EUR
- Articles in DOAJ
- 16761
- Declared review time
- 19 weeks
- Declared peer-review model
- open_review
- Official website
- https://bmccancer.biomedcentral.com
Index listings
- DOAJ · 2003-06-23
- MEDLINE · 2001-01-01
- PUBMED · 2002-03-21
- Indexing
- DOAJ · MEDLINE · PUBMED
- APC
- 3,150 EUR
- Declared review time (DOAJ)
- 19 weeks
- Actual review time (measured)
- 110 days received→accepted — computed from PubMed (n=72)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
16761
Most recent article
last month
Average review time (journal-declared via DOAJ)
19weeks
Works in OpenAlex
20651
Last recorded publication year
2026
Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
204
i10-index
13402
From OpenAlex open data (CC0).
Editorial & policy13
- Last DOAJ review date
- 2026-03-17
- Added to DOAJ
- 2003-06-23
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- LOCKSSPMC
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 100%
- ORCID iDs in current deposits
- 11%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity3
- Alternate titles
- CancerBioMed Central cancer
- Source type
- journal
- NLM unique ID (PubMed)
- 100967800
Classification2
Subjects (DOAJ)
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LCC codes
RC254-282
Subject areas
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Global Cancer Incidence and Screening
- Ferroptosis and cancer prognosis
Show all subjects (75)
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Breast Cancer Treatment Studies
- Breast Cancer Treatment Studies
- Cancer survivorship and care
- Lung Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer survivorship and care
- Global Cancer Incidence and Screening
- Global Cancer Incidence and Screening
- Cancer survivorship and care
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- Head and Neck Cancer Studies
- Cancer Cells and Metastasis
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Esophageal Cancer Research and Treatment
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Surgical Treatments
- Breast Lesions and Carcinomas
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Lung Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Endometrial and Cervical Cancer Treatments
- MicroRNA in disease regulation
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- MicroRNA in disease regulation
- Gastric Cancer Management and Outcomes
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Endometrial and Cervical Cancer Treatments
- Cancer Risks and Factors
- Endometrial and Cervical Cancer Treatments
- Cancer Risks and Factors
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Surgical Treatments
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Cervical Cancer and HPV Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cervical Cancer and HPV Research
- Glioma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
Keywords (DOAJ)
- cancer
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ